Zircol

Quick links to important sections

Zircol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zircol

Quick Facts: Zircol

Property Description
Active Ingredient Lercanidipine hydrochloride
Form Film-coated tablet
Pharmacological Class Calcium channel blocker (Dihydropyridine derivative)
Common Purpose Management of hypertension (high blood pressure)
Origin Synthetic

What is Zircol and What Type of Drug Is It?

Zircol is a sophisticated synthetic pharmaceutical preparation designed for the management of hypertension, commonly referred to as high blood pressure. It is precisely classified as a calcium channel blocker, placing it within a crucial pharmacological class of medicines that modulate the flow of calcium ions into cells. Specifically, the active ingredient, Lercanidipine, is recognized as a third-generation dihydropyridine derivative, distinguishing it from other types of calcium antagonists. This classification confirms the preparation is primarily engineered to influence the peripheral arterial system, rather than the heart muscle itself, making it a targeted therapy for the hypertensive patient population. Lercanidipine is clinically recognized for its high vascular selectivity and long duration of action.


Composition, Form, and General Antihypertensive Purpose

The medication is a single-ingredient product whose sole active ingredient is Lercanidipine hydrochloride, the chemical form responsible for the drug's therapeutic action. Zircol is supplied as a solid film-coated tablet designed for oral intake, ensuring its predictable absorption and systemic effect. Its formulation demonstrates a high lipophilicity that contributes to sustained presence at the site of action. The overall antihypertensive purpose is achieved through Lercanidipine's core function: promoting the relaxation and widening of the arteries, a process known as vasodilation. This action directly lowers the total peripheral resistance to blood flow. This reduction in resistance is the essential benefit, helping to normalize elevated high blood pressure by lessening the pressure exerted by the blood against the vessel walls.

What side effects are possible with Zircol?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety-related information for Zircol, based strictly on authoritative government regulatory documents.

Adverse Reactions by Frequency and System

The safety profile is organized by the frequency of occurrence and the body system affected. Regulatory documents classify adverse reactions into categories such as Common (affecting 1 to 10 users in 100), Uncommon, Rare, and Very Rare.

Commonly reported adverse reactions include peripheral edema (swelling of the ankles or feet), headache, and flushing. These are often related to the drug's effects on the vascular system. System-organ classes involved include Cardiac disorders, Vascular disorders, Nervous system disorders, and Gastrointestinal disorders.

Serious Adverse Reactions and Restrictions

Official documents highlight the potential for serious adverse reactions, including rare occurrences of myocardial infarction (heart attack), an increase in the frequency or severity of existing angina pectoris (chest pain), and rare hepatobiliary injury such as hepatitis or jaundice.

Safety-related limitations and contraindications formally restrict the use of Zircol in specific situations. The medicine is contraindicated (must not be used) in patients with a known allergy to the active substance, severe hypotension (very low blood pressure), cardiogenic shock, untreated congestive heart failure, and significant aortic stenosis. Use is also formally contraindicated with the medicine ciclosporin and the consumption of grapefruit or grapefruit juice. It is contraindicated for use during pregnancy and lactation (breastfeeding) and is not recommended for use in children and adolescents under 18 years of age due to a lack of data.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The official regulatory profile for Zircol (Lercanidipine) overdose is defined by the consequences of excessive vasodilation. The primary documented clinical presentations include severe hypotension, a profound drop in blood pressure which represents the most critical risk, and disturbances in heart rhythm. These cardiac effects may manifest as reflex tachycardia (an abnormally fast heart rate) or bradycardia (an abnormally slow heart rate). Additional documented signs are dizziness and somnolence (sleepiness).

Immediate Action and Treatment

In the event of a suspected overdose, regulatory guidance mandates that individuals seek immediate medical attention. The official prescribing information states that patients with anticipated moderate to severe intoxication should be observed in a high-care setting where continuous, active cardiac monitoring and frequent blood pressure measurements are required.

Treatment is limited to symptomatic and supportive measures. It is officially documented that no specific antidote is known. Due to the high protein-binding nature of the drug, procedures such as hemodialysis are not expected to be of benefit in managing the overdose. This structural profile emphasizes that external emergency intervention and life support are the primary required responses to overdose.

Therapeutic Uses of Zircol

What Zircol Treats: Main Uses and Benefits

Zircol is used in situations involving high blood pressure (hypertension).


Easing Symptoms Related to Heightened Physiological Activity

This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns related to heightened physiological activity. It is relevant for managing conditions that require short-term symptom assistance and helps to ease the overall burden of symptoms. The medicine is considered relevant for managing symptoms that create noticeable physiological strain and interfere with daily functioning.


Supporting Stability During Symptomatic Periods

Across conditions marked by increased physiological stress, this medicine is considered relevant when supportive symptom management is appropriate. In contexts involving heightened systemic burden, it contributes to improved day-to-day comfort and helps maintain a sense of stability when symptoms become more noticeable; it may assist with maintaining functional stability.


Managing Disruptive Symptom Patterns

The medicine is used to address systemic or localized discomfort and is applicable when conditions produce significant symptomatic burden. It supports patients during episodes of heightened discomfort by assisting with maintaining functional stability.


Quick Fact: Supports Systemic Discomfort Management

Eligibility and Restrictions for Use

Who can and cannot use Zircol?

The eligibility for Zircol (Lercanidipine hydrochloride) is strictly defined by regulatory guidelines based on age, reproductive status, and pre-existing medical conditions. The medicine is approved for use in adults over the age of 18 years for the management of hypertension.


Absolute Contraindications

Zircol must not be used by patients with specific severe health conditions, including:

  • Hypersensitivity to Lercanidipine or any drug in the dihydropyridine class.
  • Severe hepatic impairment or severe renal impairment (GFR < 30 ml/min), including those undergoing dialysis.
  • Untreated congestive cardiac failure, unstable angina pectoris, or recent myocardial infarction (within the last month).
  • Left ventricular outflow tract obstruction.

Restrictions and Non-Recommended Use

  • Pediatric Population: Use is not recommended in children and adolescents under 18 years because the safety and efficacy have not been established in this age group.
  • Organ Impairment: Patients with mild to moderate hepatic or renal impairment may use Zircol, but special care is required when commencing treatment.
  • Reproductive Status: Zircol is not recommended during pregnancy or lactation, and its use is contraindicated in women of child-bearing potential who are not using effective contraception.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zircol (Lercanidipine) is metabolized mainly by the CYP3A4 enzyme in the liver, which is the basis for its most significant drug and food interactions.

Category Key Interacting Substances Interaction Impact
Contraindicated Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, Ritonavir, Fluoxetine) Substantially increase Zircol plasma levels (up to 15-fold), increasing the risk of adverse effects. These combinations must be avoided.
Contraindicated Ciclosporin Causes a three-fold increase in Zircol plasma levels; this combination should not be administered together.
Contraindicated Grapefruit or Grapefruit Juice Inhibits Zircol metabolism, leading to increased plasma concentrations and a greater blood pressure-lowering effect. Must be avoided.
Use with Caution CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) Reduce Zircol plasma levels, which may decrease its antihypertensive efficacy. Blood pressure monitoring is required.
Use with Caution Other Antihypertensives, Alcohol May potentiate the blood pressure-lowering effect, requiring caution and monitoring.
Use with Caution Digoxin, Simvastatin Close clinical monitoring is advised for potential toxicity or need for dose adjustment.

Caution is also advised when Zircol is co-prescribed with other CYP3A4 substrates that have a narrow therapeutic index, such as the Class III Antiarrhythmic Drugs (e.g., Amiodarone, Quinidine, Sotalol), due to the potential for altered plasma levels.

Mechanism of Action

How Zircol Works

Zircol (Lercanidipine) acts through a targeted pharmacodynamic process that modulates arterial smooth muscle tone by interfering with fundamental cellular signaling.


Molecular Blockade of Calcium Channels

The primary mechanism involves the selective blockade (antagonism) of the L-type Voltage-Gated Calcium Channels (CaV1.2 subtype) found on the cell walls of vascular smooth muscle cells . This targeted interaction inhibits the transmembrane influx of calcium ions (Ca^2+), which are the molecular triggers for muscle contraction.


Disruption of Excitation-Contraction Coupling

By limiting the availability of intracellular calcium, the drug disrupts the excitation-contraction coupling sequence—the biological cascade that initiates muscle shortening. This suppression prevents the full activation of the muscle's contractile machinery, leading to the relaxation and widening of the peripheral arteries (vasodilation).


Reduction in Total Peripheral Resistance

The resulting vasodilation in the arterioles decreases the resistance to blood flow throughout the systemic circulation. This physiological change, known as a reduction in Total Peripheral Resistance, is the core mechanistic consequence.

Dosage and Administration Information

How to Use Zircol (Lercanidipine) — Administration Guidelines

This section outlines the instructions for using Zircol (lercanidipine).


Standard Dosing and Schedule

Feature Guideline
Route of Administration Oral use only.
Standard Starting Dose 10 mg once daily.
Dose Titration The daily dose may be increased to 20 mg if the 10 mg dose is not providing sufficient effect, but this increase should be considered after approximately two weeks of treatment.
Frequency Once a day (OD).

Administration Requirements

The use of Zircol involves specific conditions:

  • Timing with Meals: The tablet is taken at least 15 minutes before a meal, typically breakfast. Taking the dose with a high-fat meal can significantly increase the drug's absorption.
  • Intake Method: The tablet should be swallowed whole with a sufficient amount of water. If the tablet is scored, the score line is intended only to facilitate breaking for ease of swallowing, not to divide the dose into equal halves.
  • Prohibited Intake: Consumption of grapefruit or grapefruit juice is avoided while taking Zircol, as it can increase the drug's concentration in the body.

Procedural and Population-Specific Rules

  • Missed Dose: If a dose is missed, it is taken as soon as remembered, unless it is closer to the next scheduled dose. In that case, the missed dose is skipped, and the next dose taken at the regular time. A double dose is not taken to compensate for a missed one.
  • Pediatric Use: Use in children and adolescents under 18 years of age is not recommended, as safety and efficacy data are not established. Special care is required for patients with mild to moderate liver or kidney impairment, and dose adjustments may be necessary.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zircol (Lercanidipine)

The scientific research for Zircol is based on clinical trials and studies that evaluated patterns in blood pressure measurements. This overview focuses on the types of studies conducted, what outcomes they monitored, and where research remains limited, using only information cited by governmental health authorities and peer-reviewed scientific literature.


Evidence for use in Essential Hypertension (High Blood Pressure)

Research examining Zircol's use in managing essential hypertension has primarily involved Randomized Controlled Trials (RCTs). Researchers specifically monitored outcomes related to changes in the measurements of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in observed populations with mild to moderate high blood pressure.

Studies conducted during periods of increased symptom activity reported that individuals using Zircol were observed in research exploring how symptoms change over time. Specifically, studies monitored changes in blood pressure readings during the observed time intervals. The research highlights changes measured during the study period, with findings describing patterns related to the percentage of participants who achieved specific pre-defined blood pressure targets.


Long-Term Studies and Follow-Up Data

Long-term research on Zircol has explored the durability of patterns observed over extended use. The body of evidence primarily explores short-term shifts in blood pressure measurements, with limited data for tracking long-term outcomes, such as heart attack or stroke. Certainty remains low when evaluating these long-term cardiovascular outcomes.


What is Still Uncertain About Zircol's Research

Several key limitations and uncertainties are described within the research base. Long-term effects are not fully established, as follow-up durations were limited in many initial RCTs. Furthermore, comparative evidence is limited in some areas, particularly concerning sustained health patterns versus other treatments over many years. Evidence for certain groups may be less certain, as some older reports included in systematic reviews were noted to have modest sample sizes or less detailed descriptions of their methodology.

Key Studies & References

  1. Efficacy and tolerability of lercanidipine in patients with hypertension and metabolic syndrome: a subgroup analysis of the ELYPSE study

Frequently Asked Questions (FAQ)

Common questions about Zircol (FAQ)


Q: How long does Zircol typically stay in the body after the last dose is taken?

Official pharmacokinetic data indicates that the elimination half-life of the active ingredient, lercanidipine, is typically between 8 and 10 hours. The half-life describes the time required for the amount of drug in the body to be reduced by half. This duration is consistent with the drug being administered once daily.

Q: Can Zircol be taken with common over-the-counter pain relievers or cold medicines?

Regulatory sources generally do not provide comprehensive lists of every common non-prescription pain reliever or cold medicine. Official product information typically details interactions with specific prescription drug classes. Therefore, patients are usually advised to disclose all medications, including those bought over-the-counter, to a healthcare professional.

Q: Do common herbal or vitamin supplements frequently interact with Zircol?

Official drug labels indicate that strong enzyme inducers like the herbal supplement St John's Wort should be avoided, as they may reduce the effectiveness of Zircol. Beyond specific substances that affect drug metabolism, comprehensive data on interactions with general vitamins or common herbs is limited in regulatory sources.

Q: Is Zircol used for short-term or long-term conditions?

According to official regulatory documents, Zircol is approved for the management of essential hypertension (high blood pressure). Since hypertension is generally a chronic, long-term condition, the use of Zircol is often required on a continuous basis.

Q: Does Zircol fully cure the condition it is prescribed for, or does it manage symptoms?

The medicine is formally indicated for the management of high blood pressure. This means that, according to official labeling, Zircol helps control the condition and its symptoms rather than offering a complete cure.

Q: Is Zircol meant to be a standalone treatment or is it usually used in combination with other therapies?

Zircol may be used as monotherapy (taken alone). However, professional clinical guidelines often include its use as part of a combination regimen alongside other drugs to achieve optimal blood pressure goals.

Q: Is Zircol intended to address the root cause or just the symptoms of the condition?

The drug works by blocking calcium channels in the blood vessels, which causes them to relax and widen (vasodilation). This action directly reduces high peripheral resistance, addressing a key physical mechanism associated with high blood pressure.

Q: Does Zircol build up in the body over time with consistent use?

The drug's high lipid solubility (fat solubility) helps it to remain at the site of action, contributing to its sustained effect over 24 hours. This characteristic is consistent with its use in a once-daily regimen to maintain consistent control.

Q: How quickly do people typically start to notice or feel the expected effects of Zircol?

The action of lowering blood pressure generally starts on the first day the medicine is taken. However, the official product information indicates that the full therapeutic benefit is typically observed after about two weeks of continuous treatment, which is the standard time for evaluation.

Q: Is it normal if Zircol does not seem to work right away after starting treatment?

Prescribing information indicates that it is common for the full effect of the medicine not to be apparent immediately. Healthcare professionals usually assess the full effectiveness of the starting dose only after the patient has taken the medicine consistently for approximately two weeks.

Q: Is fatigue or drowsiness a known side effect of Zircol?

Official regulatory documents list fatigue (tiredness) as an uncommon adverse reaction, meaning it affects a small percentage of users. Drowsiness (somnolence) is also listed as a rare adverse reaction.

Q: Is it possible to experience withdrawal-like symptoms if Zircol use is suddenly stopped?

Regulatory guidelines suggest that if treatment needs to be stopped, it should be withdrawn gradually under the supervision of a healthcare professional. This precaution is advised for antihypertensive drugs to help prevent a rapid return or rebound of high blood pressure.

Q: Can Zircol be used safely by patients who are 65 years of age or older?

Clinical evidence cited in regulatory documents suggests that Zircol is generally tolerated in the elderly population (aged 65 and older). Official prescribing information does not generally require a specific dose adjustment solely based on advanced age.

Q: Has the FDA (or other major agency) issued any special warnings or safety advisories about Zircol use?

Official safety warnings indicate that caution may be needed for patients with pre-existing heart conditions. There have been rare reports of serious events, including an increase in the frequency or severity of existing chest pain (angina) or, very rarely, a heart attack (myocardial infarction).

Q: Is there a difference in how generic Zircol is officially reviewed compared to the brand name version?

Official guidance on generic drugs indicates that they must contain the exact same active ingredient as the brand name version. Generic versions must also be proven bioequivalent to establish that they have a similar expected clinical effect and safety profile.

How should Zircol be stored and disposed of?

How to Store and Dispose of Zircol

Zircol (lercanidipine hydrochloride) tablets must be stored according to official regulatory guidelines to preserve stability and ensure safety.


Storage Requirements

Temperature and Protection: Store the tablets at temperatures not exceeding 25 C or 30 C and keep them in a cool, dry place. The product must be protected from both light and moisture, which requires keeping the tablets in the original package or blister pack until they are ready to be taken.

Stability and Safety: Do not use Zircol after the printed expiry date (EXP) or if the tablets show visible signs of deterioration. It is a mandatory requirement to store this medicine out of the sight and reach of children.


Disposal Instructions

Unused or expired Zircol must not be thrown away with household waste or disposed of via wastewater. For correct handling of pharmaceutical waste, all unused or time-expired tablets must be returned to a pharmacist for disposal according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zircol found in:

A-Z Index: